The next focusIR Investor Webinar takes places on 14th May with guest speakers from Blue Whale Growth Fund, Taseko Mines, Kavango Resources and CQS Natural Resources fund. Please register here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksGooch & Housego Regulatory News (GHH)

Share Price Information for Gooch & Housego (GHH)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 562.00
Bid: 0.00
Ask: 0.00
Change: 0.00 (0.00%)
Spread: 8.00 (1.429%)
Open: 0.00
High: 0.00
Low: 0.00
Prev. Close: 562.00
GHH Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Acquisition of Artemis Optical

19 Jul 2023 07:00

RNS Number : 4953G
Gooch & Housego PLC
19 July 2023
 

 

For release at 7.00 am

19 July 2023

 

Gooch & Housego PLC

("G&H" or the "Company" or the "Group")

 

G&H Enhances Coatings Expertise with the Acquisition of Artemis Optical

 

 

Gooch & Housego PLC (AIM: GHH), the specialist manufacturer of optical components & systems, announces that it has entered into a conditional agreement to acquire the entire issued share capital of Artemis Optical Holdings Ltd ("Artemis") for a total consideration of up to £8.9 million. This acquisition further enhances G&H's product portfolio and creates new opportunities for vertical integration and the cross selling of our combined capabilities.

 

Artemis is a thin-film coating company renowned for its expertise in a variety of cutting-edge applications. It is recognised as a global leader in designing advanced optical filters for tailored electro-optical systems and laser protection, as well as bespoke head-up display combiners. Artemis also works with its customers to develop customised, system-enabling optical filters, mirrors and pioneering helmet mounted display patches. Artemis' products cater to the diverse needs of customers primarily in Aerospace & Defence as well as in the Industrial and Life Sciences markets.

 

Artemis operates from a modern facility near Plymouth in the UK and employs around 40 people. The newly acquired site will serve as a centre of excellence to coordinate the development of new coatings across G&H and a hugely complementary fit to the Group's existing extensive coating capabilities. 

 

This acquisition, which is aligned to G&H's new strategy, provides the Group the opportunity to offer both substrates and coating materials of the highest quality that perfectly align with their application or product requirements. By applying G&H's resources, expertise, and worldwide reach Artemis will be able to access new customers and territories for its capabilities.

 

 

Charlie Peppiatt, Chief Executive Officer of Gooch & Housego, commented:

 

"The addition of Artemis' coatings expertise to G&H's capabilities was identified in our new strategy as one of the opportunities to deliver sustainable margin growth for the Company. Artemis' renowned excellence in thin-film coatings complements our existing capabilities to enable us to deliver advanced photonics technology and unparalleled value for our customers. Together, we are well-positioned to accelerate our customer focused innovation plans and create a better world with photonics."

 

 

Terms of acquisition

 

The total consideration payable for Artemis by G&H is up to £8.9 million. This comprises an initial cash consideration of £4.5 million, funded from existing resources, together with £2.4 million of new G&H ordinary shares to be satisfied by the issue of 412,088 new G&H ordinary shares. There is a deferred contingent cash consideration of up to £2.0 million, payable based upon Artemis' performance in the two years ending 31 July 2025. The acquisition is expected to complete on 21 July 2023.

 

In its financial year ended 31 March 2023 Artemis' revenue was c.£4.3 million and adjusted EBITDA was c.£0.7 million. As at the end of June 2023 Artemis had gross assets of c£3 million.

 

This acquisition is expected to be marginally earnings enhancing in the first full financial year of G&H's ownership.

 

 

 

For further information please contact:

 

Charlie Peppiatt, Chief Executive Officer

Chris Jewell, Chief Financial Officer 

Gooch & Housego PLC

+44 (0) 1460 256440

 

Mark Court / Abigail Gilchrist

G&H@buchanan.uk.com

Buchanan

+44 (0) 20 7466 5000

 

Christopher Baird / David Anderson

Investec Bank plc

+44 (0) 20 7597 5970

 

 

Notes to editors

 

1. Gooch & Housego is a photonics technology business headquartered in Ilminster, Somerset, UK with operations in the USA and Europe. A world leader in its field, the company researches, designs, engineers and manufactures advanced photonic systems, components and instrumentation for applications in the Aerospace & Defence, Industrial, Life Sciences and Scientific Research sectors. World leading design, development and manufacturing expertise is offered across a broad range of complementary technologies.

 

2. All financial information included in this announcement is sourced from unaudited management accounts and excludes any specific items. This announcement contains certain forward-looking statements that are based on management's current expectations or beliefs as well as assumptions about future events. These are subject to risk factors associated with, amongst other things, the economic and business circumstances occurring from time to time in the countries and sectors in which G&H operates. It is believed that the expectations reflected in these statements are reasonable but they may be affected by a wide range of variables which could cause actual results, and G&H's plans and objectives, to differ materially from those currently anticipated or implied in the forward-looking statements. Investors should not place undue reliance on any such statements. Nothing in this announcement should be construed as a profit forecast.

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
ACQEASXNFDPDEEA
Date   Source Headline
1st Sep 202012:02 pmRNSPrice Monitoring Extension
3rd Jun 20202:53 pmRNSDirector/PDMR Shareholding
2nd Jun 202011:37 amRNSDirector/PDMR Shareholding
2nd Jun 20207:00 amRNSInterim Results
18th May 20207:00 amRNSNotification of Half Year Results
11th May 20207:00 amRNSAppointment of Non-Executive Director
23rd Apr 20204:23 pmRNSHolding(s) in Company
9th Apr 20203:25 pmRNSHolding(s) in Company
7th Apr 20207:00 amRNSHalf Year Trading Update
27th Mar 20204:36 pmRNSPrice Monitoring Extension
24th Mar 20204:42 pmRNSSecond Price Monitoring Extn
24th Mar 20204:36 pmRNSPrice Monitoring Extension
24th Mar 20207:00 amRNSUS Facilities Update
17th Mar 20201:22 pmRNSFremont Facility Update
16th Mar 20201:56 pmRNSDirector/PDMR Shareholding
6th Mar 20209:45 amRNSDirector Share Purchase
3rd Mar 20207:00 amRNSStreamlining of Manufacturing
19th Feb 202012:23 pmRNSResult of AGM
19th Feb 20207:00 amRNSAGM Trading Update
3rd Feb 202012:08 pmRNSIssue of Equity and Total Voting Rights
14th Jan 202010:21 amRNSGrant of LTIP Awards
27th Dec 20193:26 pmRNSDirectorate: David Bauernfeind
11th Dec 20197:00 amRNSPosting of Annual Report and AGM Notice
9th Dec 20198:50 amRNSHolding(s) in Company
3rd Dec 20197:00 amRNSPreliminary Results
20th Nov 20198:42 amRNSBlock listing Interim Review
15th Nov 20194:41 pmRNSSecond Price Monitoring Extn
15th Nov 20194:35 pmRNSPrice Monitoring Extension
11th Nov 201911:18 amRNSConfirmation of Directorate Change
8th Nov 201912:54 pmRNSTotal Voting Rights
7th Oct 20197:00 amRNSFull Year Trading Update and Results Notification
6th Aug 201912:02 pmRNSPrice Monitoring Extension
18th Jul 201910:11 amRNSChief Financial Officer Appointment Timing Update
1st Jul 201910:57 amRNSDirector/PDMR Shareholding
6th Jun 201912:58 pmRNSDirector Share Purchase
4th Jun 20194:23 pmRNSDirectors' Share Purchases
4th Jun 20197:00 amRNSDirectorate Change
4th Jun 20197:00 amRNSInterim Results
28th May 20199:52 amRNSHolding(s) in Company
9th May 20197:00 amRNSNotification of Half Year Results
30th Apr 20197:00 amRNSAppointment of Chief Financial Officer
9th Apr 20197:00 amRNSCapital Markets Day
9th Apr 20197:00 amRNSHalf Year Trading Update
28th Mar 20195:28 pmRNSDirector/PDMR Shareholding
28th Mar 20195:25 pmRNSDirector/PDMR Shareholding
28th Mar 20195:24 pmRNSDirector/PDMR Shareholding
25th Mar 20195:24 pmRNSDirector/PDMR Shareholding
13th Mar 20197:00 amRNSITL signs manufacturing agreement with OrganOx
25th Feb 201911:27 amRNSDirector Share Purchase
21st Feb 20192:58 pmRNSDirector Share Purchase

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.